Recombinant Human WT1 293 Cell Lysate

• Cat.No.: WT1-278HCL

Specification

• Description: Antigen standard for Wilms tumor 1 (WT1), transcript variant D is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
• Tag: Non

Gene Information

• Gene Name: WT1 Wilms tumor 1 [ Homo sapiens ]
• Official Symbol: WT1
• Synonyms: WT1; Wilms tumor 1; GUD; Wilms tumor protein; AWT1; WAGR; WIT 2; amino-terminal domain of EWS|last three zinc fingers of the DNA-binding domain of WT1; WT33; NPHS4; WIT-2; EWS-WT1
• Gene ID: 7490
• mRNA Refseq: NM_000378
• Protein Refseq: NP_000369
• MIM: 607102
• UniProt ID: P19544
• Chromosome Location: 11p13
• Pathway: Regulation of Telomerase, organism-specific biosystem; Transcriptional misregulation in cancer, organism-specific biosystem; Transcriptional misregulation in cancer, conserved biosystem

Reviews

10/10/2020

It has been widely employed in protein electron microscopy structure analysis, where it has demonstrated remarkable efficacy.

10/25/2019

Broad applicability make it a valuable asset for a wide range of research endeavors.

05/07/2017

Researchers can rely on the WT1 Protein to deliver reliable and reproducible results, facilitating robust data interpretation and scientific advancements.

Q&As

What therapeutic strategies are being explored for cancers with abnormal WT1 expression?

Targeted therapies and immunotherapies aimed at inhibiting or modulating WT1 expression are being investigated for their potential in cancer treatment.

In what other cancers is the WT1 protein targeted for diagnostic purposes?

Apart from Wilms' tumor, WT1 is examined in leukemia, mesothelioma, and some solid tumors as a diagnostic marker.

Can WT1 be a target for personalized cancer therapy?

Yes, understanding the WT1 status in a patient's cancer can guide the development of personalized treatment plans, potentially improving outcomes.

Are there any ongoing clinical trials focused on the WT1 protein and cancer?

Yes, there are several clinical trials exploring the role of WT1 as a therapeutic target and its potential in cancer treatment.

How does the WT1 protein contribute to the prognosis of cancer patients?

High levels of WT1 expression are often associated with poor prognosis in various cancers, indicating a more aggressive disease course.